Chronic Venous Insufficiency

Chronic venous insufficiency (CVI) is among the most prevalent vascular conditions worldwide. Varicose vein disease is common, with reported prevalence ranging from under 1% to 73% in women and from 2% to 56% in men across populations (Beebe-Dimmer et al., 2005), with complications including superficial thrombophlebitis, deep vein thrombosis, lymphangitis, post-thrombotic syndrome, and chronic venous ulceration. In the United States, venous leg ulcers alone cost payers an estimated $14.9 billion a year (Rice et al., 2014).

CVI disproportionately affects women, older adults, and individuals with occupations requiring prolonged standing. Despite available treatments (compression therapy, sclerotherapy, endovenous ablation, surgery), conservative therapy does not universally resolve pain, edema, or the progressive tissue hypoxia that leads to trophic changes and ulceration. It is in this therapeutic gap that hirudotherapy has occupied a clinical niche for over a century.

CVI is classified using the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) system. The clinical component is most relevant for treatment decisions and for matching patients to hirudotherapy evidence:

CVI results from sustained venous hypertension due to valve incompetence. The resulting pathological cascade provides multiple targets for leech therapy. Serkov attributed the mechanism to two complementary pathways: restoration of hemodynamic processes (reducing elevated venous pressure to break the “vicious circle” of impaired blood flow) and direct improvement of tissue microcirculation through SGS pharmacology:

Bapat et al. conducted the most physiologically detailed CVI study, monitoring ulcer healing, hyperpigmentation, edema, and — in a subset of 7 patients — partial oxygen pressure (pO₂) in arterial blood, venous blood, and blood extracted by leeches. This is the only study providing objective gas exchange data:

The pO₂ finding confirms that leeches preferentially extract venous blood, and the intermediate values suggest targeted decompression of the congested venous compartment rather than indiscriminate blood removal. This mechanism directly supports the use of leeches in microsurgical venous congestion management and provides physiologic justification for CVI applications.

Acute thrombophlebitis is a common complication of CVI and frequently contributes to disease progression. A Russian report by Magomedov, summarized in Baskova & Isakhanyan (2004), compared 26 patients given leeches plus standard therapy with 20 given standard therapy alone in acute lower-limb thrombophlebitis; the original publication could not be independently verified, so it cannot be regarded as strong evidence:

Post-Thrombotic Syndrome: Timing of Treatment

Flecken and Michalsen (2007) emphasize that in post-thrombotic syndrome (PTS) secondary to deep leg vein thrombosis, leeches may be applied to the affected region for superficial adjuvant therapy — but only after completion of pharmacological anticoagulant therapy. Concurrent anticoagulation constitutes a contraindication for leeching due to uncontrollable bleeding risk. Repeat treatments can be considered if the initial treatment resulted in good improvement of symptoms and prolonged therapeutic effects. To avoid wound healing problems, leeches should never be applied directly to regions with marked signs of dermatitis or ulceration.

Hirudotherapy for CVI is best understood as an adjunctive therapy integrated with established management strategies, not as a standalone treatment:

• Bapat 1998 (n=20): all ulcers healed (uncontrolled); pO₂ of leech-sucked blood was similar to venous blood
• Shchekotov 1980 (n=67): Ulcers cleared, filled with granulation tissue, epithelialized; pigmentation and scaling resolved

CVI patients require careful monitoring because venous hypertension may prolong post-detachment bleeding and impaired venous skin heals more slowly. Patients on anticoagulation for prior DVT (common in the CVI population) represent a relative contraindication requiring individual risk-benefit assessment. Patient selection guidelines are provided below.